Using ultrasound to guide radiofrequency treatment for pancreatic tumors
Official title: Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms
Run by Oslo University Hospital · NCT05243082 · Data updated 2026-11-12
This study is testing if using ultrasound to guide a special heat treatment can safely target and destroy small pancreatic tumors in patients with certain types of neuroendocrine tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 1 site (Oslo) |
| Status | Recruiting |
| Started | January 14, 2022 |
| Main results expected | January 14, 2025 |
| Study ends | November 11, 2029 |
| Registry record updated | March 30, 2023 |
| Trial ID | NCT05243082 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 with specific types of pancreatic neuroendocrine tumors that meet the inclusion criteria.
✕Probably not a fit
Patients with severe health conditions, metastatic disease, or those who are pregnant will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the feasibility and effectiveness of using endoscopic ultrasound-guided radiofrequency ablation to treat pancreatic neuroendocrine tumors classified as WHO Grade 1-2, which are 3 cm or smaller. It is a national multicenter prospective study involving multiple hospitals to gather data on this innovative treatment approach. The goal is to assess how well this method can target and destroy tumor cells while minimizing damage to surrounding tissues.
Why it matters
Potential benefit: If successful, this treatment could provide a less invasive option for patients with pancreatic neuroendocrine tumors, potentially improving outcomes and quality of life.
How similar studies have gone: While there is ongoing research in this area, this specific approach using endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age above 18 * EUS fine needle biopsy (FNB) proven pancreatic neuroendocrine tumor (PNET), WHO 2019 Grade 1-2 in patients with functioning or non-functioning tumors. Also MEN1 patients are eligible: * PNET 2-3 cm in largest diameter (Based on MRI or CT) with a Ki-67 \<5%, or: * PNET \< 2cm with Ki-67 \<10% that has shown progression during surveillance, or: * PNET 1.5-2 cm with Ki-67 \<10% in patients age \< 60 years of age, whether progression is detected or not. * Distance from the main pancreatic duct ≥2 mm, or \<2mm with a prophylactic stent in the main pancreatic duct. * Patient in good general condition, ECOG performance status 0-2 (see Appendix) * Signed written informed consent Exclusion Criteria: * Pregnancy. * Life expectancy \< 1 year * Severe hemostasis disorders * Pancreatic and/or biliary ductal dilation * Evidence of active pancreatitis * Metastatic disease, including local lymph node metastases * Use of anticoagulants that cannot be discontinued * INR \>1.5 or platelet count \<50.00 * Distance from the main pancreatic duct \<1 mm, and placement of a pancreatic stent is not possible * Patient being managed for another malignant lesion which is progressive or under treatment
Where it's running
-
Oslo University Hospital
Oslo, Norway Recruiting
Study contacts
- Study coordinator: Espen Thiis-Evensen, MD, PhD
- Email: ethiisev@ous-hf.no
- Phone: 45039399
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.